Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
CCR2 covalent NAM (AC137)
Cat.#: ASSD-137
Specifications
Description Chemokine CCR2 covalent negative allosteric modulator (NAM) binds intracellularly and forms a covalent bond with one of three proximal cysteine residues of CCR2. Apparent pKi values at CCR2 are 8.7 and 9.2 (after 4h), where a Ki shift indicates a covalent mode of action. Size 50 μg Chemical Name 2-[[4-[4-Chloro-2-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]phenoxy]benzoyl]amino]ethyl thiocyanate Molecule Weight 590.4 Molecular formula C23H16Cl2F3N3O4S2 PubChem identifier 162666730 Purity >95% Solubility Soluble in DMSO Storage Store at -20° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-135 JC-1 (AC135) 5 mg inquiry ASSD-180 Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 (AC180) 1 mg inquiry ASSD-141 MTT (AC141) 500 mg, 1 g inquiry ASSD-187 Quinaldine Red (AC187) 5 g, 25 g, 100 g, 250 g inquiry ASSD-117 Annexin V-PE Apoptosis Staining / Detection Kit (AC117) 1 kit, 100 tests inquiry ASSD-147 Rhodamine phalloidin-TRITC (AC147) 300 tests, 100μg inquiry ASSD-119 Fluorescent adenosine agonist [NECA] (AC119) 500 μg inquiry ASSD-189 7-Hydroxycoumarin-3-carboxylic acid (AC189) 100 mg inquiry ASSD-129 Fluorescent 5-HT1A antagonist [NAN-190] (AC129) 50 μg inquiry ASSD-109 Picro Sirius Red Solution (AC109) 250 mL inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket